The DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Antiviral agents active against influenza A viruses
Open accessAbstract
The recent outbreaks of avian influenza A (H5N1) virus, its expanding geographic distribution and its ability to transfer to humans and cause severe infection have raised serious concerns about the measures available to control an avian or human pandemic of influenza A. In anticipation of such a pandemic, several preventive and therapeutic strategies have been proposed, including the stockpiling of antiviral drugs, in particular the neuraminidase inhibitors oseltamivir (Tamiflu; Roche) and zanamivir (Relenza; GlaxoSmithKline). This article reviews agents that have been shown to have activity against influenza A viruses and discusses their therapeutic potential, and also describes emerging strategies for targeting these viruses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Strategies for mitigating an influenza pandemic
Ferguson, N. M., Cummings, D. A. T., Fraser, C., Cajka, J. C., Cooley, P. C., & Burke, D. S. (2006) · Nature · doi:10.1038/nature04795 · Cited by 2,187
Rational design of potent sialidase-based inhibitors of influenza virus replication
von Itzstein, M., Wu, W.-Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Van Phan, T., Smythe, M. L., White, H. F., Oliver, S. W., et al. (1993) · Nature · doi:10.1038/363418a0 · Cited by 1,862
Strategies for containing an emerging influenza pandemic in Southeast Asia
Ferguson, N. M., Cummings, D. A. T., Cauchemez, S., Fraser, C., Riley, S., Meeyai, A., Iamsirithaworn, S., & Burke, D. S. (2005) · Nature · doi:10.1038/nature04017 · Cited by 1,816
1918 Influenza: the Mother of All Pandemics
Taubenberger, J. K., & Morens, D. M. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1201.050979 · Cited by 1,686
1918 Influenza: the Mother of All Pandemics
Taubenberger, J. K., & Morens, D. M. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1209.05-0979 · Cited by 1,590
Influenza virus receptors in the human airway
Shinya, K., Ebina, M., Yamada, S., Ono, M., Kasai, N., & Kawaoka, Y. (2006) · Nature · doi:10.1038/440435a · Cited by 1,398
Avian Influenza A (H5N1) Infection in Humans
(2005) · New England Journal of Medicine · doi:10.1056/nejmra052211 · Cited by 1,285
Influenza Pandemics of the 20th Century
Kilbourne, E. D. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1201.051254 · Cited by 1,224
Kim, C. U., Lew, W., Williams, M. A., Liu, H., Zhang, L., Swaminathan, S., Bischofberger, N., Chen, M. S., Mendel, D. B., Tai, C. Y., et al. (1997) · Journal of the American Chemical Society · doi:10.1021/ja963036t · Cited by 1,100
Neuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,094
McCormick, J. B., King, I. J., Webb, P. A., Scribner, C. L., Craven, R. B., Johnson, K. M., Elliott, L. H., & Belmont-Williams, R. (1986) · New England Journal of Medicine · doi:10.1056/nejm198601023140104 · Cited by 999
Broad-Spectrum Antiviral Activity of Virazole: 1-β-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
Sidwell, R. W., Huffman, J. H., Khare, L., Allen, B., Witkowski, R., & Robins, K. (1972) · Science · doi:10.1126/science.177.4050.705 · Cited by 985
Oseltamivir Resistance during Treatment of Influenza A (H5N1) Infection
de Jong, M. D., Thanh, T. T., Khanh, T. H., Hien, V. M., Smith, G. J. D., Chau, N. V., Cam, B. V., Qui, P. T., Ha, D. Q., Guan, Y., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa054512 · Cited by 901
Antiviral Activity of 1-Adamantanamine (Amantadine)
Davies, W. L., Grunert, R. R., Haff, R. F., McGahen, J. W., Neumayer, E. M., Paulshock, M., Watts, J. C., Wood, T. R., Hermann, E. C., & Hoffmann, C. E. (1964) · Science · doi:10.1126/science.144.3620.862 · Cited by 838
The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design
Russell, R. J., Haire, L. F., Stevens, D. J., Collins, P. J., Lin, Y. P., Blackburn, G. M., Hay, A. J., Gamblin, S. J., & Skehel, J. J. (2006) · Nature · doi:10.1038/nature05114 · Cited by 813
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 786
Bright, R. A., Medina, M.-J., Xu, X., Perez-Oronoz, G., Wallis, T. R., Davis, X. M., Povinelli, L., Cox, N. J., & Klimov, A. I. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67338-2 · Cited by 725
Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes.
Field, A. K., Tytell, A. A., Lampson, G. P., & Hilleman, M. R. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.58.3.1004 · Cited by 708
Influenza: lessons from past pandemics, warnings from current incidents
Horimoto, T., & Kawaoka, Y. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1208 · Cited by 696
Isolation of drug-resistant H5N1 virus
Le, Q. M., Kiso, M., Someya, K., Sakai, Y. T., Nguyen, T. H., Nguyen, K. H. L., Pham, N. D., Ngyen, H. H., Yamada, S., Muramoto, Y., et al. (2005) · Nature · doi:10.1038/4371108a · Cited by 693
H5N1 Virus Attachment to Lower Respiratory Tract
van Riel, D., Munster, V. J., de Wit, E., Rimmelzwaan, G. F., Fouchier, R. A. M., Osterhaus, A. D. M. E., & Kuiken, T. (2006) · Science · doi:10.1126/science.1125548 · Cited by 691
Bright, R. A. (2006) · JAMA · doi:10.1001/jama.295.8.joc60020 · Cited by 671
Strategies in the design of antiviral drugs
De Clercq, E. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd703 · Cited by 652
Self-citationMatrosovich, M. N., Matrosovich, T. Y., Gray, T., Roberts, N. A., & Klenk, H.-D. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12665-12667.2004 · Cited by 606
Influenza: old and new threats
Palese, P. (2004) · Nature Medicine · doi:10.1038/nm1141 · Cited by 603
Isaacs, A., & Lindenmann, J. (2015) · The Journal of Immunology · doi:10.1093/jimmunol/195.5.1911 · Cited by 602
Mechanism of Action of T-705 against Influenza Virus
Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., & Shiraki, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.981-986.2005 · Cited by 546
Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade
Pleschka, S., Wolff, T., Ehrhardt, C., Hobom, G., Planz, O., Rapp, U. R., & Ludwig, S. (2001) · Nature Cell Biology · doi:10.1038/35060098 · Cited by 526
Kaiser, L., Wat, C., Mills, T., Mahoney, P., Ward, P., & Hayden, F. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1667 · Cited by 501
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.977-981.2002 · Cited by 501
Huggins, J. W., Hsiang, C. M., Cosgriff, T. M., Guang, M. Y., Smith, J. I., Wu, Z. O., LeDuc, J. W., Zheng, Z. M., Meegan, J. M., Wang, Q. N., et al. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/164.6.1119 · Cited by 463
Welliver, R. (2001) · JAMA · doi:10.1001/jama.285.6.748 · Cited by 463
Inhibition of influenza virus production in virus-infected mice by RNA interference
Ge, Q., Filip, L., Bai, A., Nguyen, T., Eisen, H. N., & Chen, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402486101 · Cited by 444
Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
Li, B.-J., Tang, Q., Cheng, D., Qin, C., Xie, F. Y., Wei, Q., Xu, J., Liu, Y., Zheng, B.-J., Woodle, M. C., et al. (2005) · Nature Medicine · doi:10.1038/nm1280 · Cited by 433
Early administration of oral oseltamivir increases the benefits of influenza treatment
Aoki, F. Y. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg007 · Cited by 424
Ives, J. A. L., Carr, J. A., Mendel, D. B., Tai, C. Y., Lambkin, R., Kelly, L., Oxford, J. S., Hayden, F. G., & Roberts, N. A. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00053-0 · Cited by 379
Protection against lethal influenza virus challenge by RNA interference in vivo
Tompkins, S. M., Lo, C.-Y., Tumpey, T. M., & Epstein, S. L. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402630101 · Cited by 378
Antivirals and antiviral strategies
Clercq, E. D. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro975 · Cited by 370
Salomon, R., Franks, J., Govorkova, E. A., Ilyushina, N. A., Yen, H.-L., Hulse-Post, D. J., Humberd, J., Trichet, M., Rehg, J. E., Webby, R. J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051938 · Cited by 348
Hayden, F. G., Belshe, R., Villanueva, C., Lanno, R., Hughes, C., Small, I., Dutkowski, R., Ward, P., & Carr, J. (2004) · The Journal of Infectious Diseases · doi:10.1086/381128 · Cited by 334
Resistance of influenza viruses to neuraminidase inhibitors — a review
MCKIMMBRESCHKIN, J. (2000) · Antiviral Research · doi:10.1016/s0166-3542(00)00103-0 · Cited by 320
Selection of Influenza Virus Mutants in Experimentally Infected Volunteers Treated with Oseltamivir
Gubareva, L. V., Kaiser, L., Matrosovich, M. N., Soo‐Hoo, Y., & Hayden, F. G. (2001) · The Journal of Infectious Diseases · doi:10.1086/318537 · Cited by 318
Influenza Viruses Resistant to the Antiviral Drug Oseltamivir: Transmission Studies in Ferrets
Herlocher, M. L., Truscon, R., Elias, S., Yen, H., Roberts, N. A., Ohmit, S. E., & Monto, A. S. (2004) · The Journal of Infectious Diseases · doi:10.1086/424572 · Cited by 292
McKimm-Breschkin, J., Trivedi, T., Hampson, A., Hay, A., Klimov, A., Tashiro, M., Hayden, F., & Zambon, M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2264-2272.2003 · Cited by 291
Ichinohe, T., Watanabe, I., Ito, S., Fujii, H., Moriyama, M., Tamura, S.-I., Takahashi, H., Sawa, H., Chiba, J., Kurata, T., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2910-2919.2005 · Cited by 272
Yen, H.-L., Herlocher, L. M., Hoffmann, E., Matrosovich, M. N., Monto, A. S., Webster, R. G., & Govorkova, E. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.10.4075-4084.2005 · Cited by 248
The Origins of Pandemic Influenza — Lessons from the 1918 Virus
Belshe, R. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058281 · Cited by 234
Sialidase Fusion Protein as a Novel Broad-Spectrum Inhibitor of Influenza Virus Infection
Malakhov, M. P., Aschenbrenner, L. M., Smee, D. F., Wandersee, M. K., Sidwell, R. W., Gubareva, L. V., Mishin, V. P., Hayden, F. G., Kim, D. H., Ing, A., et al. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1470-1479.2006 · Cited by 233
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases
Reeves, P. M., Bommarius, B., Lebeis, S., McNulty, S., Christensen, J., Swimm, A., Chahroudi, A., Chavan, R., Feinberg, M. B., Veach, D., et al. (2005) · Nature Medicine · doi:10.1038/nm1265 · Cited by 226
Susceptibilities of Antiviral-Resistant Influenza Viruses to Novel Neuraminidase Inhibitors
Mishin, V. P., Hayden, F. G., & Gubareva, L. V. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4515-4520.2005 · Cited by 216
Tomassini, J., Selnick, H., Davies, M. E., Armstrong, M. E., Baldwin, J., Bourgeois, M., Hastings, J., Hazuda, D., Lewis, J., & McClements, W. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.12.2827 · Cited by 188
Tanner, J. A., Zheng, B.-J., Zhou, J., Watt, R. M., Jiang, J.-Q., Wong, K.-L., Lin, Y.-P., Lu, L.-Y., He, M.-L., Kung, H.-F., et al. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.01.006 · Cited by 176
Chand, P., Kotian, P. L., Dehghani, A., El-Kattan, Y., Lin, T.-H., Hutchison, T. L., Babu, Y. S., Bantia, S., Elliott, A. J., & Montgomery, J. A. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010277p · Cited by 174
The CPSF30 Binding Site on the NS1A Protein of Influenza A Virus Is a Potential Antiviral Target
Twu, K. Y., Noah, D. L., Rao, P., Kuo, R.-L., & Krug, R. M. (2006) · Journal of Virology · doi:10.1128/jvi.80.8.3957-3965.2006 · Cited by 174
Cyclopentane Neuraminidase Inhibitors with Potent In Vitro Anti-Influenza Virus Activities
Smee, D. F., Huffman, J. H., Morrison, A. C., Barnard, D. L., & Sidwell, R. W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.743-748.2001 · Cited by 170
Yen, H., Monto, A. S., Webster, R. G., & Govorkova, E. A. (2005) · The Journal of Infectious Diseases · doi:10.1086/432008 · Cited by 169
Ilyushina, N. A., Bovin, N. V., Webster, R. G., & Govorkova, E. A. (2006) · Antiviral Research · doi:10.1016/j.antiviral.2006.01.012 · Cited by 157
Synthesis and Antiviral Activity Evaluation of Some New Aminoadamantane Derivatives. 2
Kolocouris, N., Kolocouris, A., Foscolos, G. B., Fytas, G., Neyts, J. H., Padalko, E., Balzarini, J. M., Snoeck, R., Andreï, G., & Clercq, E. D. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950891z · Cited by 157
Marjuki, H., Alam, M. I., Ehrhardt, C., Wagner, R., Planz, O., Hd, K., Ludwig, S., & Pleschka, S. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510233200 · Cited by 152
Anti-influenza virus activity of peramivir in mice with single intramuscular injection
Bantia, S., Arnold, C., Parker, C. D., Upshaw, R., & Chand, P. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.10.002 · Cited by 149
Deng, T., Sharps, J. L., Fodor, E., & Brownlee, G. G. (2005) · Journal of Virology · doi:10.1128/jvi.79.13.8669-8674.2005 · Cited by 143
Yang, H., Kim, S.-K., Kim, M., Reche, P. A., Morehead, T. J., Damon, I. K., Welsh, R. M., & Reinherz, E. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523220 · Cited by 134
Govorkova, E. A., Fang, H., Tan, M., & Webster, R. G. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4855-4863.2004 · Cited by 132
Heterocyclic rimantadine analogues with antiviral activity
Zoidis, G., Fytas, C., Papanastasiou, I. P., Foscolos, G. B., Fytas, G., Padalko, E. Y., Clercq, E. D., Naesens, L. M. J., Neyts, J. H., & Kolocouris, N. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.12.056 · Cited by 128
Barroso, L. F., Treanor, J. J., Gubareva, L. V., & Hayden, F. G. (2005) · Antiviral Therapy · doi:10.1177/135965350501000805 · Cited by 127
Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus
Tumpey, T. M., García‐Sastre, A., Mikulasova, A., Taubenberger, J. K., Swayne, D. E., Palese, P., & Basler, C. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212519699 · Cited by 127
Safety and Efficacy of Nebulized Zanamivir in Hospitalized Patients with Serious Influenza
NIAID Collaborative Antiviral Study Group, Ison, M. G., Gnann, J. W., Nagy-Agren, S. E., Treanor, J. J., Payá, C. V., Steigbigel, R. T., Elliott, M. J., Weiss, H. L., & Hayden, F. G. (2003) · Antiviral Therapy · doi:10.1177/135965350300800301 · Cited by 118
Kati, W. M., Montgomery, D., Carrick, R. J., Gubareva, L. V., Maring, C. J., McDaniel, K. F., Steffy, K. R., Molla, A., Hayden, F. G., Kempf, D. J., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1014-1021.2002 · Cited by 103
In Vivo Influenza Virus-Inhibitory Effects of the Cyclopentane Neuraminidase Inhibitor RWJ-270201
Sidwell, R. W., Smee, D. F., Huffman, J. H., Barnard, D. L., Bailey, K. W., Morrey, J. D., & Babu, Y. S. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.3.749-757.2001 · Cited by 98
Zürcher, T. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl321 · Cited by 97
Macdonald, S. J. F., Cameron, R., Demaine, D. A., Fenton, R. J., Foster, G., Gower, D., Hamblin, J., Hamilton, S., Hart, G. J., Hill, A. P., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm040891b · Cited by 93
In Vitroandin VivoActivities of T-705 and Oseltamivir against Influenza Virus
Takahashi, K., Furuta, Y., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., & Shiraki, K. (2003) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020301400502 · Cited by 90
Total Synthesis of A-315675: A Potent Inhibitor of Influenza Neuraminidase
Hanessian, S., Bayrakdarian, M., & Luo, X. (2002) · Journal of the American Chemical Society · doi:10.1021/ja0126226 · Cited by 83
Macdonald, S. J. F., Watson, K. G., Cameron, R., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4542-4549.2004 · Cited by 82
Synthesis and anti-Influenza virus activity of 7-O-Alkylated derivatives related to zanamivir
Honda, T., Masuda, T., Yoshida, S., Arai, M., Kaneko, S., & Yamashita, M. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00329-3 · Cited by 68
Avian Influenza Viruses and their Implication for Human Health
Kaye, D., & Pringle, C. R. (2004) · Clinical Infectious Diseases · doi:10.1086/427236 · Cited by 67
Chand, P., Bantia, S., Kotian, P. L., El-Kattan, Y. A., Lin, T., & Babu, Y. S. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.03.048 · Cited by 66
Heterocyclic rimantadine analogues with antiviral activity
Stamatiou, G., Foscolos, G. B., Fytas, G., Kolocouris, A., Kolocouris, N., Pannecouque, C. C., Witvrouw, M., Padalko, E. Y., Neyts, J. H., & Clercq, E. D. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2003.09.024 · Cited by 64
Absence of Interferon in Lungs from Fatal Cases of Influenza
Baron, S., & Isaacs, A. (1962) · BMJ · doi:10.1136/bmj.1.5270.18 · Cited by 60
Stamatiou, G., Kolocouris, A., Kolocouris, N., Fytas, G., Foscolos, G. B., Neyts, J. H., & Clercq, E. D. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00388-2 · Cited by 59
Maring, C. J., Stoll, V. S., Zhao, C., Sun, M., Krueger, A. C., Stewart, K. D., Madigan, D. L., Kati, W. M., Xu, Y., Carrick, R. J., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049276y · Cited by 59
Hayden, F. G., Schlepushkin, A. N., & Pushkarskaya, N. L. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.1.53 · Cited by 56
Masuda, T., Shibuya, S., Arai, M., Yoshida, S., Tomozawa, T., Ohno, A., Yamashita, M., & Honda, T. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)01039-9 · Cited by 56
Polymer-bound 6′ sialyl-N-acetyllactosamine protects mice infected by influenza virus
Gambaryan, A. S., Boravleva, E. Y., Matrosovich, T. Y., Matrosovich, M. N., Klenk, H., Moiseeva, E. V., Tuzikov, A. B., Chinarev, A. A., Pazynina, G. V., & Bovin, N. V. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.07.008 · Cited by 54
Molla, A., Kati, W. M., Carrick, R. J., Steffy, K. R., Shi, Y. X., Montgomery, D., Gusick, N. J., Stoll, V. S., Stewart, K. D., Ng, T. I., et al. (2002) · Journal of Virology · doi:10.1128/jvi.76.11.5380-5386.2002 · Cited by 50
Intravenous ribavirin by constant infusion for serious influenza and parainfluenzavirus infection.
Hayden, F. G., Sable, C. A., Connor, J. D., & Lane, J. (1996) · PubMed · Cited by 46
Are the 2-Isomers of the Drug Rimantadine Active Anti-Influenza a Agents?
Zoidis, G., Kolocouris, N., Foscolos, G. B., Kolocouris, A., Fytas, G., Karayannis, P., Padalko, E. Y., Neyts, J. H., & Clercq, E. D. (2003) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020301400305 · Cited by 46
Chand, P., Kotian, P. L., Morris, P. E., Bantia, S., Walsh, D. A., & Babu, Y. S. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.01.042 · Cited by 43
Synthesis of influenza neuraminidase inhibitors.
Abdel‐Magid, A. F., Maryanoff, C. A., & Mehrman, S. J. (2001) · PubMed · Cited by 21
OXFORD, J. S., Balasingam, S., & Lambkin, R. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh037 · Cited by 20
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Self-citationStructural basis of influenza virus fusion inhibition by the antiviral drug Arbidol
Kadam, R. U., & Wilson, I. A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617020114 · Cited by 435
Klein, S. L. (2012) · BioEssays · doi:10.1002/bies.201200099 · Cited by 284
Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.076 · Cited by 257
Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?
Hayden, F. (2009) · Clinical Infectious Diseases · doi:10.1086/591851 · Cited by 256
Metadata
- Authors
- De Clercq, E.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-12-01
- Volume
- 5
- Issue
- 12
- Pages
- 1015-1025
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2128924487
- Cited by
- 668
- References
- 92
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.